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Abstract
Aims/hypothesis Insulin resistance in skeletal muscle is
linked to mitochondrial dysfunction in obesity and type 2
diabetes. Emerging evidence indicates that reversible phos-
phorylation regulates oxidative phosphorylation (OxPhos)
proteins. The aim of this study was to identify and quantify
site-specific phosphorylation of the catalytic beta subunit of
ATP synthase (ATPsyn-β) and determine protein abundance
of ATPsyn-β and other OxPhos components in skeletal
muscle from healthy and insulin-resistant individuals.
Methods Skeletal muscle biopsies were obtained from lean,
healthy, obese, non-diabetic and type 2 diabetic volunteers
(each group n=10) for immunoblotting of proteins, and
hypothesis-driven identification and quantification of phos-
phorylation sites on ATPsyn-β using targeted nanospray
tandem mass spectrometry. Volunteers were metabolically
characterised by euglycaemic–hyperinsulinaemic clamps.
Results Seven phosphorylation sites were identified on
ATPsyn-β purified from human skeletal muscle. Obese
individuals with and without type 2 diabetes were charac-
terised by impaired insulin-stimulated glucose disposal
rates, and showed a ∼30% higher phosphorylation of
ATPsyn-β at Tyr361 and Thr213 (within the nucleotide-
binding region of ATP synthase) as well as a coordinated
downregulation of ATPsyn-β protein and other OxPhos
components. Insulin increased Tyr361 phosphorylation of
ATPsyn-β by ∼50% in lean and healthy, but not insulin-
resistant, individuals.
Conclusions/interpretation These data demonstrate that
ATPsyn-β is phosphorylated at multiple sites in human
skeletal muscle, and suggest that abnormal site-specific
phosphorylation of ATPsyn-β together with reduced con-
tent of OxPhos proteins contributes to mitochondrial
dysfunction in insulin resistance. Further characterisation
of phosphorylation of ATPsyn-β may offer novel targets of
treatment in human diseases with mitochondrial dysfunc-
tion, such as diabetes.
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UQCRC1 Ubiquinol-cytochrome c reductase core
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Introduction
Proteins in the mitochondrial oxidative phosphorylation
(OxPhos) machinery play a crucial role in energy produc-
tion, generation of reactive oxygen species and apoptosis.
Through the concerted action of the electron transport chain
and ATP synthase, OxPhos is responsible for the production
of more than 90% of cellular ATP. Impaired mitochondrial
OxPhos is involved in a wide range of human pathologies,
including neurodegenerative diseases, cancer, diabetes and
ageing [1]. Skeletal muscle, which is rich in mitochondria,
accounts for ∼25% of whole body oxygen consumption in
humans in the resting state [2]. Moreover, skeletal muscle is
the major site of glucose uptake (∼80%) in response to
insulin [3], and correspondingly is an important site
of insulin resistance in obesity and type 2 diabetes [4–6].
Insulin resistance in skeletal muscle is characterised by
impaired insulin stimulation of glucose transport and
glycogen synthesis, and shows a strong correlation with
intramyocellular lipid content [7, 8]. Recently, a number of
studies have provided evidence for a reduced content and
functional capacity of muscle mitochondria in obesity and
type 2 diabetes [9–13], and it has been hypothesised that
mitochondrial dysfunction could be responsible for the
accumulation of lipid metabolites [14]. An accumulation of
lipid metabolites could, in turn, partially explain the insulin
signalling defects reported in skeletal muscle in obesity and
type 2 diabetes [9, 14]. Microarray-based studies of muscle
gene expression in patients with type 2 diabetes and high-
risk individuals have consistently shown a coordinated
downregulation of OxPhos genes and suggested that a
reduced expression of the peroxisome proliferator-activated
receptor, gamma, coactivator 1, alpha gene (PPARGC1A)
could play a key role for impaired mitochondrial biogenesis
[15–17]. Whether a similar coordinated downregulation is
seen at the protein level and to what extent mitochondrial
dysfunction involves altered post-translational modifica-
tions of OxPhos proteins remain to be clarified.
In higher organisms, reversible phosphorylation of
enzymes plays a crucial role for hormonal regulation of
cell signalling pathways, e.g. insulin signalling [18]. There
is now evidence that a number of mitochondrial proteins
including subunits in all respiratory complexes (I–V) of
OxPhos are phosphorylated, and potentially regulated by
several kinases and phosphatases localised to mitochondria
[19, 20]. Using a two-dimensional gel-based proteomic
approach, we previously reported reduced protein content
and altered phosphorylation of the catalytic beta subunit in
the ATP synthase complex (ATPsyn-β) in muscle of
patients with type 2 diabetes [21]. In that study, a single
phosphopeptide was identified with the potential phosphor-
ylation site, Thr213, in the nucleotide-binding region of
ATPsyn-β.
We recently developed a targeted approach for identify-
ing and quantifying multiple phosphorylation sites on
insulin receptor substrate 1 in human skeletal muscle using
nanospray tandem mass spectrometry (MS/MS) [22–24].
Here, we applied a modification of this proteomic approach
to discover novel phosphorylation sites on ATPsyn-β and
to examine whether the phosphorylation of muscle ATPsyn-
β at specific sites is altered in obesity and type 2 diabetes,
or in response to physiological hyperinsulinaemia. More-
over, we studied whether changes in ATPsyn-β protein
content are coordinated with changes in protein levels of
other OxPhos proteins.
Methods
Study cohort Ten healthy lean and ten obese volunteers
were carefully matched to ten patients with type 2 diabetes
participating in the study (Table 1). Patients with type 2
diabetes were treated either by diet alone or diet in
combination with sulfonylurea, metformin or insulin, which
were withdrawn 1 week prior to the study. Patients with
type 2 diabetes were all negative for GAD65 antibody and
without signs of diabetic retinopathy, nephropathy, neurop-
athy or macrovascular complications. The lean and obese
controls had normal glucose tolerance and no family history
of diabetes. All participants had normal results on screening
blood tests of hepatic and renal function, and were
instructed to refrain from strenuous physical activity for a
period of 48 h before the experiment. Informed consent was
obtained from all individuals before participation. The
study was approved by the local ethics committee and
was performed in accordance with the Declaration of
Helsinki.
Metabolic studies and muscle biopsies The euglycaemic–
hyperinsulinaemic clamp studies were performed after an
overnight fast as described in detail previously [5, 6]. In
brief, a 2 h basal tracer equilibration period was followed
by infusion of insulin at a rate of 40 mU m−2 min−1 for 4 h.
Using this protocol, euglycaemia at a plasma glucose
concentration of 5.0-5.5 mmol/l and physiological hyper-
insulinaemia at a serum insulin concentration of
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∼400 pmol/l were obtained in all groups during the insulin-
stimulated steady-state period. The studies were combined
with indirect calorimetry, and rates of total glucose
disposal, glucose and lipid oxidation, and non-oxidative
glucose metabolism were calculated as described [5, 6].
Serum insulin and plasma glucose, triacylglycerol, NEFA
and adiponectin were assayed as described [5, 6]. A muscle
biopsy from each individual was obtained from the vastus
lateralis muscle in the basal state after the 2 h basal tracer
equilibration period using a modified Bergström needle
with suction under local anaesthesia. Muscle samples were
immediately blotted free of blood, fat and connective tissue
and frozen in liquid nitrogen within 30 s. The muscle
biopsy specimens were homogenised while still frozen in
an ice-cold buffer as previously described [25].
SDS-PAGE and immunoblotting Fifty micrograms of mus-
cle protein lysates were separated by 10% SDS-PAGE gels
and transferred to nitrocellulose membranes. After blocking
with TRIS-buffered saline plus 0.05% Tween 20 (TBST)
with 5% non-fat dry milk for 1 h at 4°C, the membranes
were washed with TBST, and then incubated for 1 h in
TBST with 5% non-fat dry milk with primary antibodies
against the proteins NADH-ubiquinone oxidoreductase
chain 6 (ND6), succinate dehydrogenase complex, subunit
A, flavoprotein (SDHA), ubiquinol-cytochrome c reductase
core protein I (UQCRC1), ATP synthase beta (ATP5B) and
ATP synthase alpha (ATP5A1) (Molecular Probes, Eugene,
OR, USA) and β-actin (Cell Signaling Technology,
Beverly, MA, USA) following the manufacturer’s recom-
mendations. The protein bands on the membranes were
quantified by densitometry (VersaDoc Imaging System,
model 5000: BioRad Laboratories, Hercules, CA, USA).
An internal control of previously extracted human muscle
was used in each gel to normalise for variations in signals
across different membranes. β-Actin was used to correct for
potential differences in blood contamination of the muscle
samples and assure equal loading.
Immunoprecipitation of ATPsyn-β Protein G agarose beads
(25 μg; SigmaAldrich, St Louis, MO) were prepared by
washing twice with 1 ml PBS (GIBCO, cat. no. 10010-023;
Invitrogen, Carlsbad, CA, USA). Mouse monoclonal ATP
synthase β antibody (Abcam, Cambridge, UK) in 300 μl
PBS was added to beads and mixed end over end for 1 h at
room temperature. The antibody-conjugated beads were
washed twice with 1 ml PBS while kept on ice. Two
milligrams of muscle lysate protein diluted in 400 μl
Table 1 Clinical and metabolic characteristics
Characteristics Lean controls Obese controls Type 2 diabetes
Male/female 5/5 6/4 6/4
Age (years) 50.8±1.0 49.1±1.5 49.9±1.5
BMI (kg/m2) 24.2±0.5 32.7±1.1** 33.5±1.1**
Plasma glucose (mmol/l) 5.7±0.1 5.7±0.2 10.0±0.6**,††
Serum insulin (pmol/l) 24.3±5.7 54.2±5.3* 94.6±10.1**,††
HbA1c (%) 5.5±0.1 5.4±0.1 7.6±0.5
**,††
HDL-cholesterol (mmol/l) 1.8±0.1 1.5±0.2 1.4±0.0*
Plasma triacylglycerol (mmol/l) 1.1±0.2 1.4±0.2 1.9±0.4
Plasma adiponectin (mg/l) 10.6±1.6 9.6±1.9 5.3±0.6*
Total glucose disposal, basal (mmol m−2 min−1) 0.45±0.02 0.45±0.02 0.48±0.01
Total glucose disposal, clamp (mmol m−2 min−1) 1.96±0.10 1.36±0.13** 0.76±0.08**,††
Glucose oxidation, basal (mmol m−2 min−1) 0.28±0.04 0.31±0.04 0.24±0.03
Glucose oxidation, clamp (mmol m−2 min−1) 0.76±0.06 0.57±0.04* 0.37±0.03**,†
Non-oxidative glucose metabolism, basal (mmol m−2 min−1) 0.17±0.04 0.14±0.04 0.24±0.03
Non-oxidative glucose metabolism, clamp (mmol m−2 min−1) 1.19±0.09 0.79±0.09** 0.39±0.08**,††
Lipid oxidation, basal (mg m−2 min−1) 44±3 43±4 53±3
Lipid oxidation, clamp (mg m−2 min−1) 11±3 22±4 41±3**,††
Plasma NEFA, basal (mmol/l) 0.54±0.07 0.51±0.06 0.52±0.02
Plasma NEFA, clamp (mmol/l) 0.03±0.00 0.05±0.01 0.10±0.02**,††
Data represent means±SEM
Study participants were studied by a 4 h euglycaemic–hyperinsulinaemic clamp combined with indirect calorimetry
*p<0.05, **p<0.01 vs lean controls
† p<0.05, †† p<0.01 vs obese individuals
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homogenisation buffer were mixed end over end with the
antibody-conjugated beads overnight at 4°C, and washed
with 1 ml PBS. The beads were then washed four times
with 1 ml PBS and 15 µl SDS 2X sample buffer was added.
Denaturing was performed by incubating the samples at 37°
C for 30 min. Lower denaturing temperatures (i.e. 37°C)
prevents the reduction of the disulphide bond between the
immunoglobulin heavy chains, resulting in a shift in the
IgG electrophoretic migration (from ∼50 KDa to ∼90–
100 KDa), removing as much of the antibody as possible
from the ∼50 kDa band of ATPsyn-β. The immunopreci-
pitates were resolved on 10% SDS polyacrylamide gels.
For mass spectrometry analysis, gels were stained with
Coomassie Blue for protein visualisation.
In-gel digestion The band containing ATPsyn-β was
excised and cut into 1 mm cubes for digestion with trypsin.
Trypsin digestion of protein within gel slices and prepara-
tion of the samples for MS were performed as described
previously [25, 26]. Three 10 fmol/µl peptides were added
to serve as internal standards (Bradykinin Fragment 2-9,
B1901, β-Sheet Breaker Peptide, S7563 and Anaphylatoxin
C3a fragment, A8651; Sigma Chemical Co., St Louis, MO,
USA).
Mass spectrometry HPLC-electron spray ionisation (ESI)-
MSn was performed on a hybrid linear ion trap (LTQ)-
Fourier transform ion cyclotron resonance (FTICR) mass
spectrometer (LTQ FT, Thermo Fisher; San Jose, CA,
USA) fitted with a PicoView nanospray source (New
Objective, Woburn, MA, USA) as described previously
[25, 26].
A ‘top-ten’ data-dependent MS/MS approach was used
to identify ATPsyn-β peptides and to obtain their HPLC
retention times. In a top-ten scan protocol, a full scan
spectrum (survey scan) is acquired followed by collision-
induced dissociation (CID) mass spectra of the ten most
abundant ions in the survey scan. Thus, a large number of
tandem mass spectra are acquired during the course of each
analysis. For the experiments used in the current report, the
survey scan was acquired using the FTICR mass analyser in
order to obtain high mass accuracy data. From this initial
analysis, a list of potential phosphorylated peptides was
generated based on detected serine/threonine-containing
peptides of ATPsyn-β. For localisation of sites of phos-
phorylation, a scan protocol of one survey scan (FTICR),
followed by six targeted MS/MS scans (CID spectra of
specified m/z values that were acquired using the LTQ mass
analyser). Ions in the target list are fragmented in the whole
HPLC-ESI-MS/MS run (90 min) to ensure the detection of
the phosphopeptides. Seven potential phosphopeptides
were successfully monitored this way in a single run.
Although di-phosphorylation and tri-phosphorylation were
considered, only monophosphorylation was detected. For
quantification, the following multi-segment strategy was
employed: one survey scan, followed by six targeted CID
scans. In order to assess the relative quantities of a large
number of phosphopeptides in each experiment and yet still
maintain acceptable mass analysis cycle times, the targeted
m/z values were grouped into segments based on their
expected HPLC retention times. Included in the target list
were the 2+ charge states of six representative peptides of
ATPsyn-β selected from the prominent ions reproducibly
observed in the top-ten data-dependent tandem-MS analysis
(see Electronic supplementary material [ESM] Table 1).
These six representative peptides were used as internal
standards for the amount of total ATPsyn-β protein content
in the samples and used for relative quantification of the
phosphopeptides. They were selected according to the
following criteria: (1) detected by HPLC-ESI-MS with
high intensity among ATPsyn-β peptides; (2) no missed
cleavage observed; (3) no methionine in the sequence to
avoid variability due to methionine oxidisation and no N-
terminal Gln residues. The 2+ or 3+ ions of the phospho-
peptides of interest were placed on the target list. The 2+
ions of the standard peptides were also placed on the target
list. The CID spectra were acquired in the centroid mode.
Experiments were performed to validate the MS peak area-
based phosphorylation quantification approach (ESM
Fig. 1).
Tandem mass spectra were extracted from Xcalibur
‘RAW’ files and charge states were assigned using the
Extract_MSN script that is a component of Xcalibur 2.0
SR2 (Thermo Fisher; San Jose, CA, USA). The fragment
mass spectra were then searched against the human
SwissProt_v52.2 database (16,135 entries) using Mascot
(Matrix Science, London, UK; version 2.1). The search
variables that were used were: 10 ppm mass tolerance for
precursor ion masses and 0.5 Da for product ion masses;
digestion with trypsin; a maximum of two missed tryptic
cleavages; variable modifications of oxidation of methio-
nine and phosphorylation of serine, threonine and tyrosine.
Cross-correlation of Mascot search results with X! Tandem
was accomplished with Scaffold (version Scaffold-
01_06_19; Proteome Software, Portland, OR, USA).
Probability assessment of peptide assignments and protein
identifications were made through use of Scaffold. Only
peptides with Q 95% probability were considered.
Statistical analysis Statistical analysis was performed using
SSSP for Windows version 10.0. Results are given as
means±SEM. Statistical evaluation of clinical and metabol-
ic characteristics and OxPhos protein content was per-
formed, where appropriate, by paired Student’s t test or
one-way ANOVA using the Tukey’s post hoc testing.
Differential phosphorylation of ATPsyn-β was assessed in
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eight experiments by calculating the relative changes
between the lean healthy participants, the obese non-
diabetic participants and the patients with type 2 diabetes
before and after insulin stimulation within each experiment.
Statistical comparison between groups was performed using
the Kruskal–Wallis test (ANOVA) and the post-hoc Mann–
Whitney U test. The effect of insulin within each group was
assessed by the Wilcoxon signed-rank test. The relation-
ships between continuous variables were examined by
calculation of Pearson’s correlation coefficients. Differ-
ences between groups were considered statistically signif-
icant at p<0.05.
Results
Clinical and metabolic characteristics Patients with type 2
diabetes had significantly higher fasting levels of HbA1c,
plasma glucose and serum insulin compared with both lean
and obese individuals, whereas fasting plasma adiponectin
and HDL-cholesterol concentrations were lower compared
with lean individuals only (Table 1). Serum insulin levels
were also significantly higher in obese than in lean
individuals. There were no differences in fasting levels of
plasma triacylglycerol or NEFA between the groups.
Basal rates of total glucose disposal, glucose oxidation,
lipid oxidation and non-oxidative glucose metabolism were
similar in the three groups. In the insulin-stimulated state
during the euglycaemic–hyperinsulinaemic clamp studies,
total glucose disposal, glucose oxidation and non-oxidative
glucose metabolism were significantly reduced in type 2
diabetic patients compared with obese and lean controls,
and in obese compared with lean individuals (Table 1). In
the group of diabetic patients, the ability of insulin to
suppress plasma levels of NEFA and rates of lipid oxidation
was significantly impaired compared with both groups of
non-diabetic individuals.
Identification of phosphorylation sites on human ATPsyn-
β Although we routinely obtained nearly 80% coverage of
ATPsyn-β (Fig. 1a; ESM 1), only one phosphopeptide
containing Thr213 was detected in a data-dependent
analysis that did not include targeted MS/MS (see below).
However, many ATPsyn-β peptides containing serine/
threonine/tyrosine residues were detected in the data-
dependent analysis. Since any peptide with serine/
threonine/tyrosine residues has the potential to be phos-
phorylated, we predicted that low abundance phosphopep-
tides might be detected using a ‘targeted’ MS scan strategy
based on addition of 80 Da (H3PO4–H2O) to the mass of
1 MLGFVGRVAA APASGALRRL TPSASLPPAQ LLLRAAPTAV HPVRDYAAQT
51 IVAVIGAV VDVQFDEGLP PILNALEVQG R LVLEVA SPSPKAGAAT GR ETR
101 QHLGESTVRT IAMDGTEGLV RGQKVLDSGA PIKIPVGPET LGRIMNVIGE
151 PIDERGPIKT KQFAPIHAEA PEFMEMSVEQ EILVTGIKVV DLLAPYAKGG
201 IGLFGGAGV GKTVLIMELI NNVAKAHGGY SVFAGVGERT REGNDLYHEM K
251 IESGVINLKD ATSKVALVYG QMNEPPGARA RVALTGLTVA EYFRDQEGQD
301 VLLFIDNIFR FTQAGSEVSA LLGRIPSAVG YQPTLATDMG TMQERITTTK
351 KGSITSVQAI YVPADDLTDP APATTFAHLD ATTVLSRAIA ELGIYPAVDP 
401 LDSTSRIMDP NIVGSEHYDV ARGVQKILQD YKSLQDIIAI LGMDELSEED
451 KLTVSRARKI QRFLSQPFQV AEVFTGHMGK LVPLKETIKG FQQILAGEYD
501 HLPEQAFYMV GPIEEAVAKA DKLAEEHSS 
Thr213
Tyr269
Thr312
Thr475
Tyr361Tyr230
Tyr395
Precursor
Nucleotide-binding
region (206–213)
a
b
Fig. 1 Human ATPsyn-β is phosphorylated at multiple sites.
Coverage map of peptides detected in tryptic digests of human muscle
ATPsyn-β in three experiments using HPLC-nanospray-LTQ-FTICR
MS/MS analysis (a). Detected peptides are shown in red, and
phosphorylation sites are shown in green. The underlined sequence
is the nucleotide-binding region, and the first 47 amino acids (italic)
represent the mitochondrial precursor region. No phosphorylation sites
were found in the precursor region (b). Among the three Pfam
domains of ATPsyn-β (http://pfam.sanger.ac.uk, accessed 30 June
2009), no phosphorylation sites were found in the N-terminal domain
(position 63–129). Six phosphorylation sites, Thr213, Tyr230, Tyr269,
Thr312, Tyr361 and Tyr395, were found in the central domain
(position 185–405), of which Thr213 is located in the nucleotide-
binding region of ATPsyn-β. One phosphorylation site, Thr475, was
found in the C-terminal domain (position 418–525)
Site Novel site Sequence
Thr213 No IGLFGGAGVGKpTVLIMELINNVAK
Thr312 No FpTQAGSEVSALLGR
Thr475 Yes FLSQPFQVAEVFpTGHMGK
Tyr230 Yes AHGGpYSVFAGVGER
Tyr269 Yes VALVpYGQMNEPPGAR
Tyr361 Yes GSITSVQAIpYVPADDLTDPAPATTFAHLDATTVLSR
Tyr395 Yes AIAELGIpYPAVDPLDSTSR
Table 2 The phosphopeptides
identified in ATPsyn-β immu-
nopurified from human skeletal
muscle and the corresponding
localisation of the seven phos-
phorylation sites identified
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Fig. 2 Tandem mass spectra of
quantified phosphopeptides.
Tandem mass spectra of the
phosphopeptides (a) pThr213
[MS/MS m/z 837.4 (3+)],
(b) pTyr361 [MS/MS m/z
1265.6 (3+)] and (c) pThr475
[MS/MS m/z 707.0 (3+)]
detected in tryptic digests of
ATPsyn-β (encoded by ATP5B)
immunoprecipitated from a
human muscle biopsy. *Loss of
H3PO4 (98 Da) from the indi-
cated fragment. Mox, oxidised
methionine
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each detected ATPsyn-β peptide that contained serine,
threonine or tyrosine. Based on this, we constructed a
hypothesis-driven strategy with various potential phospho-
peptide m/z values in a target list, thereby greatly improving
our ability to detect phosphopeptides [22–24]. This ap-
proach allowed us to detect six additional, distinct
phosphorylation sites (Fig. 1b; Table 2). Among these, five
sites have not been reported previously. From Scaffold
analysis of the database search results, all phosphopeptides
were identified at the 95% confidence level (ESM Tables 2,
3, 4, 5, 6, 7, 8 and 9). Three phosphorylated threonine
residues, Thr213, Thr312 and Thr475 were detected.
Thr213 is located in the nucleotide-binding region of the
catalytic beta subunit of ATP synthase (Fig. 1b). Four
phosphorylated tyrosine residues, Tyr230, Tyr269, Tyr361
and Tyr395 were also identified. Tandem mass spectra
illustrating localisation of the sites of phosphorylation are
given in Fig. 2 for the quantified phosphopeptides and in
ESM Fig. 2 for the other phosphopeptides. NetworKIN
analysis (www.networkin.info, accessed 25 June 2009)
suggested protein kinase C, delta (PRKCD) and DNA-
dependent protein kinase (PRKDC) as potential kinases for
Thr312 phosphorylation. No kinases were predicted for the
other sites.
Effect of insulin resistance and insulin on phosphorylation
of ATPsyn-β As detailed in the ESM 1, we have validated
the MS peak area-based approach for phosphorylation
quantification. We applied this approach to investigate
differential phosphorylation of ATPsyn-β among lean
healthy, obese non-diabetic, and type 2 diabetic individuals
under both basal conditions and after 4 h insulin infusion.
ATPsyn-β was immunoprecipitated from 2 mg protein
lysate from each muscle biopsy and subjected to HPLC-
ESI-MS/MS. Basal phosphorylation of Thr213, which lies
within the nucleotide-binding region of ATPsyn-β,
was increased by 37% in obese non-diabetic participants
(p=0.003) and by 22% in patients with type 2 diabetes
(p=0.010) compared with lean individuals (ANOVA; p=
0.003; Fig. 3). Basal Tyr361 phosphorylation was increased
by 32% in obese non-diabetic individuals (p=0.028) and
patients with type 2 diabetes (p=0.021) compared with lean
healthy controls (ANOVA; p=0.031). No differences in
basal Thr475 phosphorylation were observed between the
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Fig. 3 Increased basal phosphorylation of ATPsyn-β at Thr213 and
Tyr361 in insulin-resistant muscle. Site-specific phosphorylation of
ATPsyn-β in skeletal muscle biopsies obtained from lean healthy,
obese non-diabetic and type 2 diabetic individuals (n=8 in each
group) under basal conditions was quantified using targeted nanospray
tandem mass spectrometry (see ESM 1). a Phosphorylation at Thr213
in the nucleotide-binding region; b phosphorylation at Tyr361 in the
central domain; and c phosphorylation at Thr475 in the C-terminal
domain of ATPsyn-β. Data are expressed as mean±SEM. **p≤0.01
and †p<0.03 vs lean controls
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Fig. 4 Insulin increases phosphorylation of ATPsyn-β at Tyr361 in
healthy muscle. The effect of 4 h physiological hyperinsulinaemia
(% change) on the site-specific phosphorylation of ATPsyn-β in
skeletal muscle biopsies obtained from lean healthy and obese non-
diabetic individuals, and patients with type 2 diabetes (n=8 in each
group) before and after an euglycaemic–hyperinsulinaemic clamp
were assessed by targeted nanospray tandem mass spectrometry (see
ESM 1). a Insulin-mediated change (%) in the phosphorylation at
Thr213 in the nucleotide-binding region; b phosphorylation at Tyr361
in the central domain; and c phosphorylation at Thr475 in the C-
terminal domain of ATPsyn-β. Data are expressed as mean±SEM.
†p=0.012 and ‡p=0.036
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groups. Interestingly, physiological hyperinsulinaemia for
4 h increased Tyr361 phosphorylation 46% in lean healthy
individuals (p=0.012), while a 24% decrease was seen in
obese individuals (p=0.036), and no change in patients
with type 2 diabetes (Fig. 4). Insulin had no effect on
Thr213 or Thr475 phosphorylation in any group.
Coordinated reduction in abundance of ATPsyn-β and
subunits of complex I, II, III and V Immunoblotting was
performed to examine whether changes in protein level of
ATPsyn-β in obesity and type 2 diabetes might be
coordinated with alterations in protein levels of other
subunits in respiratory complexes I–V (Fig. 5). ATPsyn-β
protein showed a significant trend to decrease from lean, to
obese and type 2 diabetic individuals (ANOVA; p=0.023).
Similar significant decreasing trends were observed for
protein levels of complex I (ND6; ANOVA; p=0.004),
complex II (SDHA; ANOVA; p=0.003), complex III
(UQCRC1; ANOVA; p=0.021) and ATP synthase alpha
(ATP5A1; ANOVA; p=0.003). Post hoc analysis showed
that there were no significant differences between obese
non-diabetic individuals and patients with type 2 diabetes,
whereas most of the subunits were significantly decreased
in obese and diabetic individuals compared with lean
controls. Correlation analysis showed that protein level of
ATPsyn-β was significantly associated with the levels of
proteins ND6, SDHA, UQCRC1 and ATP5A1 (r=0.63–
0.77, all p<0.001), providing further evidence for a
coordinated transcriptional and translational regulation of
these OxPhos components.
Discussion
Using our targeted MS/MS based approach for mapping of
phosphorylation sites, we identified seven phosphorylation
sites on human muscle ATPsyn-β. Quantification revealed
a ∼30% increase in the basal phosphorylation of ATPsyn-β
at Tyr361 and Thr213 in obesity and type 2 diabetes, and
demonstrated a ∼50% increase in phosphorylation at
Tyr361 in response to insulin in lean healthy individuals.
Moreover, we found a coordinated downregulation of
muscle ATPsyn-β and other OxPhos proteins in obesity
and type 2 diabetes. Our results indicate that phosphoryla-
tion of human muscle ATPsyn-β may be an important
regulatory mechanism of electron-coupled ATP synthesis,
and that disturbances in this regulation in addition to
reduced content of OxPhos proteins may contribute to the
pathogenesis of insulin resistance and type 2 diabetes.
The F1 portion of the ATP synthase complex is located
in the mitochondrial matrix and consists of five subunits
with the stoichiometry α3β3γδε. The beta subunits contain
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Fig. 5 Coordinated downregulation of ATPsyn-β and other OxPhos
proteins in insulin-resistant muscle. Immunoblotting of OxPhos
proteins in skeletal muscle biopsies obtained from lean healthy, obese
non-diabetic and type 2 diabetic individuals under basal conditions
(n=10 in each group). Protein levels of: a complex I subunit, ND6 (a);
a complex II subunit, SDHA (b); a complex III subunit, UQCRC1 (c);
and two complex V subunits, ATP5B (e) and ATP5A1 (d). f
Representative blots of the OxPhos proteins and actin in muscle from
lean, obese and type 2 diabetic participants. The protein content is
shown as arbitrary units and data are expressed as mean ± SEM.
*p=0.05, **p=0.01 and †p=0.06 vs lean controls. Cx, muscle from an
internal control used to normalise for variation in signal intensities
across gels; Le, lean; Ob, obese; T2D, type 2 diabetic
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the catalytic sites essential for the binding of ADP and Pi
and synthesis of ATP. Here, we demonstrate that human
ATPsyn-β is phosphorylated at multiple specific sites in
vivo. These results extend our previous work [21] and that
of several other studies that have used various phospho-
labelling techniques or phosphopeptide identification by
MS, which have provided indirect evidence for serine/
threonine/tyrosine phosphorylation of ATPsyn-β in yeast,
plants and mammalian tissues and cell lines [27–35].
The present study provides the first mapping of phos-
phorylation sites on human ATPsyn-β. Recently, five
specific phosphorylation sites were assigned to ATPsyn-β
in rabbit heart muscle using phosphopeptide enrichment
and MS/MS technology [27]. However, although all sites
were targeted in our analyses, of these we could only
confirm the phosphorylation at Thr312 in human skeletal
muscle. In addition to Thr213 [21] and Thr312 [27], we
identified five novel phosphorylation sites at Thr475,
Tyr230, Tyr269, Tyr361 and Tyr395, respectively. These
data suggest the possibility that reversible phosphorylation
of human ATPsyn-β at specific serine/threonine/tyrosine
residues regulates the catalytic activity of ATP synthase,
and hence ATP synthesis. Moreover, phosphorylation of
ATPsyn-β may play a role for its translocation and import
into the mitochondrial matrix, assembly of the ATP
synthase complex, dimerisation [32] and formation of
OxPhos supercomplexes, stability and degradation [19].
Further studies are needed to address the precise functional
consequences of these phosphorylations, and the mitochon-
drial kinases and phosphatases involved.
The present data represent, to our knowledge, the first
evidence that a mitochondrial OxPhos protein may be
differently phosphorylated in insulin resistant human
muscle in vivo. The magnitude (∼30%) of the increase in
basal phosphorylation of ATPsyn-β at Thr213 and Tyr361
corresponds to other defects in muscle in type 2 diabetes,
e.g. impaired insulin-stimulated glycogen synthase activity
[4, 5]. There are experimental data indicating that phos-
phorylation of ATPsyn-β, in particular at serine residues,
lowers ATP synthase activity. Consumption of soy proteins,
which have been linked to a decreased risk of type 2
diabetes and certain types of cancer, caused decreased
phosphorylation of ATPsyn-β and increased ATP synthase
activity in the liver of rats [31]. In rat renal cells, PRKCA-
mediated serine phosphorylation of ATPsyn-β was associ-
ated with a decreased ATP synthase activity in vitro [30].
Moreover, in plant mitochondria, the binding of recombi-
nant 14-3-3 protein to phosphorylated serine/threonine-
residues on ATPsyn-β inhibited ATP synthase activity [36].
Of interest, Thr213 is located within the nucleotide-binding
region, indicating that phosphorylation at this site may
interfere with the binding of ADP and Pi to the catalytic
sites on ATPsyn-β, and therefore could interfere with ATP
synthesis. This suggests that increased phosphorylation at
Thr213 could potentially contribute to impaired mitochon-
drial ATP synthesis in obesity and type 2 diabetes.
However, further studies are warranted to investigate
whether the observed changes in phosphorylation are
paralleled by changes in ATP synthase activity and OxPhos
in insulin resistant human skeletal muscle.
In this study we also demonstrated that at least one
phosphorylation site on ATPsyn-β is altered by infusion of
insulin. The ∼50% increase in phosphorylation of Tyr361 in
lean individuals is a physiological relevant increase, and
indicates that it may affect the rate of ATP production. A
number of tyrosine-specific kinases and phosphatases have
been localised to mitochondria, and a role for tyrosine
phosphorylation in the regulation of mitochondrial function
has gained increasing attention [19, 37]. Tyrosine phos-
phorylation of two subunits of cytochrome c oxidase (CcO)
has been shown to either inactivate or activate complex IV
activity [19]. Therefore, it is difficult to predict how insulin-
induced Tyr361 phosphorylation of ATPsyn-β might
affect ATP synthase activity in human skeletal muscle.
There is evidence that TNF-α stimulation induces
tyrosine phosphorylation of ATPsyn-β in murine fibro-
blasts [34], and that TNF-α inhibits OxPhos through
tyrosine phosphorylation of subunit I of CcO in bovine
and murine cells [38]. For a number of reasons, however,
it is tempting to speculate that insulin-mediated Tyr361
phosphorylation of ATPsyn-β might stimulate OxPhos.
First, 2 h of physiological hyperinsulinaemia increases
muscle ATP production in healthy individuals, as evaluated
by nuclear magnetic resonance spectroscopy [39, 40]. The
same effect is seen in isolated muscle mitochondria obtained
from healthy individuals after 4 h of insulin infusion,
suggesting that this response it not solely due to increased
substrate fluxes [41]. Analogous to the diminished effect of
insulin on Tyr361 phosphorylation in insulin-resistant
individuals in our study, there is an impaired effect of
insulin on ATP production in patients with type 2 diabetes
and high-risk individuals in these studies [39–41]. Second,
the increased basal Tyr361 phosphorylation of ATPsyn-β
could be a consequence of chronic hyperinsulinaemia and,
as seen with increased basal tyrosine phosphorylation of the
insulin receptor and IRS-1 in insulin-resistant muscle [4,
42], attenuate the ability to further increase Tyr361
phosphorylation in response to insulin. This could, however,
also be a saturable effect, which does not necessarily imply
a lack of insulin action. Taken together, our data suggest the
possibility that insulin may regulate mitochondrial function
through cell signalling in human muscle in vivo, and that
these effects may be diminished in obesity and type 2
diabetes concomitant with reduced insulin-mediated glucose
disposal. Additional studies are warranted to establish the
precise role of these phosphorylation sites, as well as how
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they might affect mitochondrial function and insulin
sensitivity in human muscle.
The finding that a ∼30–50% lower protein content of
ATPsyn-β was coordinated with a similar decrease in other
both nuclear- and mitochondrial-encoded OxPhos proteins
clearly supports microarray-based studies of gene expres-
sion [15–17] and other reports that have provided evidence
for a reduced mitochondrial content in skeletal muscle in
type 2 diabetes and obesity [9, 10, 13, 43]. Together with
the altered phosphorylation of ATPsyn-β, our data extend
previous observations by showing that mitochondrial
dysfunction coexists at the transcriptional, translational
and post-translational level in insulin-resistant human
muscle. Based on the data provided in the present study,
we cannot exclude the possibility that these findings might
be completely unrelated. Nevertheless, the finding of
abnormal phosphorylation of ATPsyn-β at specific sites in
obesity and type 2 diabetes could potentially explain the
impaired respiration per mitochondrion, as recently
reported [11, 12]. Based on previous studies of type 2
diabetic patients and matched controls, there is no clear
evidence that an intrinsic defect in mitochondrial function is
located exclusively to ATP synthase. In fact, it seems to be
substrate specific and also present in uncoupled mitochon-
dria, suggesting that a defect in complex I–IV contributes to
mitochondrial dysfunction [11, 12]. This suggests the
possibility that insulin and insulin resistance affects other
subunits in complex I–IV and ATP synthase by phosphor-
ylation or other post-translational modifications. Moreover,
the changes in phosphorylation of ATPsyn-β and protein
levels of ATPsyn-β and other OxPhos proteins were similar
in type 2 diabetic and non-diabetic obese individuals. This
strongly indicates that other factors contribute to the lower
insulin-stimulated glucose metabolism in type 2 diabetes
compared with obesity alone. There is evidence that a lower
protein content of ATPsyn-β may affect beta cell and
adipocyte function [44–47], and it is also a hallmark of
most human carcinomas [48, 49]. Thus, aberrant phosphor-
ylation of ATPsyn-β may have putative consequences in
other tissues in insulin-resistant individuals as well as in
other disorders.
In summary, our data demonstrate that a hypothesis-driven
MS/MS-based approach for the identification and quantifi-
cation of phosphorylated serine/threonine/tyrosine residues is
well suited for the analysis of proteins from small human
tissue samples. We identified seven phosphorylation sites on
human ATPsyn-β in skeletal muscle. Of these, five phos-
phorylation sites are novel. Quantification allowed us to
discover increased basal Tyr361 and Thr213 phosphorylation
of ATPsyn-β in obesity and type 2 diabetes. The ability of
physiological hyperinsulinaemia to increase Tyr361 phos-
phorylation in lean healthy individuals was absent in obesity
and type 2 diabetes. These abnormalities in obesity and type
2 diabetes were seen together with impaired insulin-
stimulated glucose disposal and a coordinated downregula-
tion of OxPhos proteins. Our data indicate a role for
perturbations in the phosphorylation of ATPsyn-β in mito-
chondrial dysfunction in skeletal muscle insulin resistance.
Future characterisation of the phosphorylation of ATPsyn-β
may offer novel targets of treatment and improved diagnosis
and prognosis of human diseases characterised by mitochon-
drial dysfunction, such as diabetes.
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